Regentatlantic Capital LLC Biogen Inc. Transaction History

Regentatlantic Capital LLC

$3.34 Billion
Q3 2022

A detailed history of Regentatlantic Capital LLC transactions in Biogen Inc. stock. As of the latest transaction made, Regentatlantic Capital LLC holds 4,905 shares of BIIB stock, worth $774,499. This represents 0.04% of its overall portfolio holdings.

Number of Shares

4,905

Previous 5,103 3.88%

Holding current value

$774,499

Previous $1.04 Million 25.84%

% of portfolio

0.04%

Previous 0.03%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $38,548 - $53,155	-198 Reduced 3.88%	4,905 $1.31 Million
Q2 2022 Aug 15, 2022	BUY	$187.54 - $223.02 $260,868 - $310,220	1,391 Added 37.47%	5,103 $1.04 Million
Q1 2022 May 02, 2022	SELL	$193.77 - $244.14 $359,830 - $453,367	-1,857 Reduced 33.35%	3,712 $782,000
Q4 2021 Jan 27, 2022	SELL	$223.92 - $287.77 $275,197 - $353,669	-1,229 Reduced 18.08%	5,569 $1.34 Million
Q3 2021 Nov 15, 2021	BUY	$282.99 - $369.05 $34,241 - $44,655	121 Added 1.81%	6,798 $1.92 Million
Q2 2021 Aug 12, 2021	SELL	$259.0 - $414.71 $77,700 - $124,413	-300 Reduced 4.3%	6,677 $2.31 Million
Q1 2021 Apr 29, 2021	SELL	$242.95 - $284.63 $261,657 - $306,546	-1,077 Reduced 13.37%	6,977 $1.95 Million
Q4 2020 Feb 04, 2021	SELL	$236.26 - $355.63 $138,448 - $208,399	-586 Reduced 6.78%	8,054 $1.97 Million
Q3 2020 Oct 13, 2020	SELL	$264.77 - $305.71 $97,170 - $112,195	-367 Reduced 4.07%	8,640 $2.45 Million
Q2 2020 Aug 13, 2020	BUY	$258.66 - $342.55 $87,168 - $115,439	337 Added 3.89%	9,007 $2.41 Million
Q1 2020 May 14, 2020	SELL	$268.85 - $341.04 $30,380 - $38,537	-113 Reduced 1.29%	8,670 $2.74 Million
Q4 2019 Feb 04, 2020	SELL	$220.06 - $304.07 $49,293 - $68,111	-224 Reduced 2.49%	8,783 $2.61 Million
Q3 2019 Oct 22, 2019	BUY	$217.44 - $243.88 $132,203 - $148,279	608 Added 7.24%	9,007 $2.1 Million
Q2 2019 Jul 23, 2019	BUY	$219.29 - $241.72 $643,616 - $709,448	2,935 Added 53.72%	8,399 $1.96 Million
Q1 2019 May 03, 2019	BUY	$216.71 - $338.96 $211,508 - $330,824	976 Added 21.75%	5,464 $1.29 Million
Q4 2018 Jan 30, 2019	SELL	$278.5 - $352.75 $160,137 - $202,831	-575 Reduced 11.36%	4,488 $1.35 Million
Q3 2018 Oct 30, 2018	SELL	$293.51 - $383.83 $18,197 - $23,797	-62 Reduced 1.21%	5,063 $1.79 Million
Q2 2018 Jul 31, 2018	BUY	$257.52 - $306.91 $115,111 - $137,188	447 Added 9.56%	5,125 $1.49 Million
Q1 2018 Apr 23, 2018	SELL	$260.13 - $367.91 $27,313 - $38,630	-105 Reduced 2.2%	4,678 $1.28 Million
Q4 2017 Jan 23, 2018	SELL	$307.64 - $344.58 $92,292 - $103,374	-300 Reduced 5.9%	4,783 $1.52 Million
Q3 2017 Oct 25, 2017	BUY	$281.15 - $329.69 $1.43 Million - $1.68 Million	5,083	5,083 $1.59 Million

Others Institutions Holding BIIB

# of Institutions

1,036

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $22.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Regentatlantic Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Regentatlantic Capital LLC with notifications on news.

Account

Regentatlantic Capital LLC Biogen Inc. Transaction History